Considering that p53 controls the G1 checkpoint and p53 is often mutated in cancer cells, tumor cells can take advantage of the S and G2 checkpoints to repair RT damage, and for this reason, combining radiosensitizer drugs with RT can cancel the G2 checkpoint [36]. The gene discussed is TP53; the disease is cancer.